<DOC>
	<DOCNO>NCT00352027</DOCNO>
	<brief_summary>The main purpose protocol estimate percentage patient intermediate risk Hodgkin lymphoma survive free disease ( Event-free survival ) three year treatment multi-agent chemotherapy ( Stanford V ) low-dose , tailored-field radiation therapy . The hypothesis study treatment result 80 % patient alive free disease three year start treatment .</brief_summary>
	<brief_title>Chemotherapy With Low-Dose Radiation Pediatric Hodgkin Lymphoma</brief_title>
	<detailed_description>Treatment Plan Description : Adriamycin 25 mg/m2 IV Day 1 week 1 , 3 , 5 , 7 , 9 , 11 Vinblastine 6 mg/m2 IV Day 1 week 1 , 3 , 5 , 7 , 9 , 11 Nitrogen Mustard 6mg/m2 IV Day 1 week 1 , 5 , 9 Cyclophosphamide 650 mg/m2 IV Day 1 week 1 , 5 , 9 ( Nitrogen Mustard available due national shortage ) Vincristine 1.4 mg/m2 IV Day 1 week 2 , 4 , 6 , 8 , 10 , 12 Bleomycin 5 units/m2 IV Day 1 week 2 , 4 , 6 , 8 , 10 , 12 Etoposide 60 mg/m2 IV Days 1,2 week 3 , 7 , 11 Prednisone* 40 mg/m2/day divide 3 dos PO Every day week 1-12 G-CSF ( need case severe myelo-suppression require treatment delay ) 5 mcg/kg SC Days 3-13 , 16-26 , 29-39 , 42-52 , 55-65 , 68-78 ( clinically indicate ) * Prednisone taper foreseen last 2 week therapy . Patients treat 12 week Stanford V chemotherapy schedule outline . Patients receive radiation therapy completion 12 week chemotherapy . The radiation dose individual nodal site base response 8 week chemotherapy : 15 Gy area achieve complete response 25.5 Gy achieve less complete response , patient bulky mediastinal mass .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Nitrogen Mustard Compounds</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Patient le equal 21 year age Patient confirm diagnosis previously untreated Hodgkin lymphoma Has Ann Arbor stage IB , IIIA , IA/IIA extranodal extension , multiple nodal involvement ( 3 site ) , bulky mediastinal adenopathy . Patients favorable risk feature Patients unfavorable risk feature Patients receive prior therapy Hodgkin lymphoma .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Hodgkin 's Disease</keyword>
</DOC>